Sana Biotechnology, Inc.
For the period ended Sep 30, 2025. Filed Nov 6, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2025 · Filed Nov 6, 2025
SANA$2.37+1.3%Stored close · as of Nov 6, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
9. Accrued liabilities
Accrued compensation and accrued expenses and other current liabilities consist of the following:
| September 30, 2025 | December 31, 2024 | |
|---|---|---|
| (in thousands) | ||
| Accrued compensation: | ||
| Accrued bonuses | $6,264 | $7,704 |
| Accrued paid time off | 2,537 | 3,151 |
| Accrued payroll | 1,996 | 3,021 |
| Other accrued compensation | 499 | 573 |
| Total accrued compensation | $11,296 | $14,449 |
| Accrued expenses and other current liabilities: | ||
| Accrued research and development services | $4,712 | $10,493 |
| Accrued professional fees | 1,948 | 993 |
| Other accrued current liabilities | 1,331 | 1,754 |
| Total accrued expenses and other current liabilities | $7,991 | $13,240 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.